Tr1X Announces FDA Clearance of IND Application for TRX103, an Allogeneic Engineered Tr1 Treg Cell Therapy for Treatment-Refractory Crohn’s Disease.

Blue shape

You might also be interested in...

October 22, 2024

Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?

View

View

September 18, 2024

Tr1X to Participate at Upcoming Healthcare Investment Conferences

View

View

November 10, 2022

Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases

View

View